Bayer Partners with NVIDIA-Backed AI Drug Discovery Firm Iambic Therapeutics

Today,Bayer and Iambic Therapeutics Announce Drug Discovery Collaboration, Leveraging Iambic’s AI-Driven Platform for Novel Drug Discovery

This collaboration will leverage Iambic’s AI-driven drug discovery platform, including its flagship AI technologies Enchant and NeuralPLexer, to identify novel druggable sites and differentiated molecules for targets that are traditionally difficult to drug, thereby enhancing Bayer’s early-stage pipeline.

Iambic Therapeutics was founded inIn early 2020,Headquartered in San Diego, United States, the company was founded by two chemistry professors.

In June 2024, the company completed a $150 millionSeries B financing, with the total cumulative funding reaching$200 million, with investors includingNVIDIA, the Global AI Hegemon.

Iambic Therapeutics has built a renownedForInsightAn R&D platform integrating artificial intelligence and physics to create more reliable and accurate models for deeper exploration of the chemical domain; the platform is primarily divided into four components.

NeuralPLexer: Predicting protein–ligand complexes, including binding-induced conformational responses, to reveal novel mechanisms of action, allosteric sites, and cryptic pockets

OrbNet: AI-Accelerated Quantum Chemistry for Calculating Protein-Ligand Binding Energies

PropANE: A Lead Compound Parameter Optimization Model Capable of Training on Dozens of Drug Properties

Magnet: Generate Molecular Designs

The company's molecular design software, Magnet, can design in a single step1024 molecules, and integrated with wet labs to refine molecular predictions based on test results,A design-manufacture-test cycle typically takes 9 days.

Iambic'sThe generative model NeuralPLexer is designed forPrediction of protein-ligand complexes is also included in this collaboration.

The two parties will advance the development of select small-molecule programs, starting in the fields of oncology, gastroenterology, and inflammation. The potential total value of this collaboration is up to$1.7 billion。

In addition to Takeda, Iambic also collaborates with companies including Revolution Medicines, Jazz Pharmaceuticals, and Lundbeck.

Recommended Reading